A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
- Author(s)
- Frentzas, S; Gan, HK; Cosman, R; Coward, J; Tran, B; Millward, M; Zhou, Y; Wang, W; Xia, D; Wang, ZM; Li, B; Xia, M; Desai, J;
- Details
- Publication Year 2023-10-11,Volume 4,Issue #11,Page 101242
- Journal Title
- Cell Reports Medicine
- Publication Type
- Research article
- Abstract
- Simultaneous inhibition of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) with bispecific antibodies may improve efficacy over single-agent treatment while limiting toxicity. Cadonilimab is a humanized, bispecific antibody targeting PD-1 and CTLA-4. This is a phase 1 study of cadonilimab including dose escalation (n = 39) and dose expansion (n = 80). One dose-limiting toxicity event is observed, with the maximum tolerated dose not reached. 6 mg/kg cadonilimab once every 2 weeks is established as the recommended dose for future studies. The most common treatment-related adverse event is infusion-related reaction (18.5%), mostly grade 1/2 in severity. The incidences of any grade and grade >/=3 immune-related adverse events are 44.5% and 6.7%, respectively. The confirmed overall response rate is 13.4%, and the median duration of response is 12.9 months. Cadonilimab is well tolerated and showed promising efficacy in patients with advanced solid tumors. This study is registered with ClinicalTrials.gov: NCT03261011.
- Publisher
- Cell Press
- Keywords
- Ctla-4; Pd-1; advanced solid tumors; bispecific antibody; cadonilimab; immune checkpoint inhibitor
- Department(s)
- Medical Oncology
- PubMed ID
- 37852261
- Publisher's Version
- https://doi.org/10.1016/j.xcrm.2023.101242
- Open Access at Publisher's Site
https://doi.org/10.1016/j.xcrm.2023.101242- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-11-30 06:12:30
Last Modified: 2023-11-30 06:21:19